Suffering from dust-mite allergies? Hang on, there's hope for a long-term treatment: a vaccine being developed is on track.

Cytos Biotechnology AG announced
today positive follow-up results from its phase IIa study with CYT005-AllQbG10 to treat allergic
diseases. The phase IIa trial in 20 patients with allergic rhinoconjunctivitis and asthma due to house
dust mite allergy evaluated the safety, tolerability and exploratory efficacy of a 10 week treatment with 300g CYT005-AllQbG10 in conjunction with house dust mite allergen.
The follow-up results obtained 8 months after start of treatment (i.e. 24 weeks after the last
injection) show that the powerful efficacy achieved with CYT005-AllQbG10 treatment offers
significant therapeutic benefit for an extended period of time.

Of course, the drug is just under Phase 2 trials. It's still a long wait til it finds its way to the drugstore, if at all.

[Soource: Cytos, pdf file]